Advertisement
Advertisement
BMRN
BioMarin Pharmaceuticals Inc
60.87
USDSponsored
-0.25
-0.42%
Mar 09, 15:59 UTC -4
Closed
After-Market
60.25
-0.62
-1.01%
BMRN Earnings Reports
Positive Surprise Ratio
BMRN beat 29 of 41 last estimates.
71%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$796.41M
/$0.96
Implied change from Q4 25 (Revenue/ EPS)
-8.94%
/-500.00%
Implied change from Q1 25 (Revenue/ EPS)
+6.88%
/+1.05%
BioMarin Pharmaceuticals Inc earnings per share and revenue
On Feb 23, 2026, BMRN reported earnings of -0.24 USD per share (EPS) for Q4 25, missing the estimate of 0.63 USD, resulting in a -137.68% surprise. Revenue reached 874.57 million, compared to an expected 844.44 million, with a 3.57% difference. The market reacted with a -0.48% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 17 analysts forecast an EPS of 0.96 USD, with revenue projected to reach 796.41 million USD, implying an decrease of -500.00% EPS, and decrease of -8.94% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Contineum Therapeutics, Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.49
Surprise
-18.41%
Lineage Cell Therapeutics, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.05
Actual
$0.00
Surprise
+100.00%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.56
Surprise
-5.44%
Coherus Oncology, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.35
Actual
-$0.34
Surprise
+4.76%
Anixa Biosciences, Inc.
Report Date
Mar 09, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.08
Surprise
+17.44%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were BioMarin Pharmaceuticals Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, BioMarin Pharmaceuticals Inc reported EPS of -$0.24, missing estimates by -137.68%, and revenue of $874.57M, 3.57% above expectations.
How did the market react to BioMarin Pharmaceuticals Inc's Q4 2025 earnings?
The stock price moved down -0.48%, changed from $62.92 before the earnings release to $62.62 the day after.
When is BioMarin Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for BioMarin Pharmaceuticals Inc's next earnings report?
Based on 17
analysts, BioMarin Pharmaceuticals Inc is expected to report EPS of $0.96 and revenue of $796.41M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement